Company Description
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.
The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson’s disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities.
It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin’s lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors.
The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.
Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2013 |
| IPO Date | May 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 256 |
| CEO | Vladimir Coric |
Contact Details
Address: 215 Church Street New Haven, Connecticut 06510 United States | |
| Phone | 203 404 0410 |
| Website | biohaven.com |
Stock Details
| Ticker Symbol | BHVN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001935979 |
| CUSIP Number | G11196105 |
| ISIN Number | VGG1110E1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vladimir Coric M.D. | Chairman and Chief Executive Officer |
| Matthew Buten | Chief Financial Officer |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer |
| Kimberly Gentile | Senior Vice President of Clinical Operations |
| Deb Young | Senior Director of Regulatory Affairs and Operations |
| George C. Clark CPA | Vice President and Chief Accounting Officer |
| Jennifer Porcelli | Vice President of Investor Relations |
| Warren Volles J.D. | General Counsel and Chief Legal Officer |
| Clifford Bechtold M.S. | President, GM of Biohaven Ireland and Chief Compliance Officer |
| John Tilton | Chief Commercial Officer of Rare Diseases |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 18, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 3, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |